News | Cardiac Diagnostics | January 25, 2018

Five Health Indicators Are Enough to Predict Cardiovascular Risk, Mount Sinai Researchers Report

Fuster-BEWAT score could be an affordable, painless alternative in developing countries without access to laboratory data

Five Health Indicators Are Enough to Predict Cardiovascular Risk, Mount Sinai Researchers Report

January 25, 2018 – In a large population study that was the first of its kind, researchers found that a simple tool not requiring laboratory tests, the Fuster-BEWAT score, is as effective as the American Heart Association-recommended ICHS (Ideal Cardiovascular Health Index), which includes blood analysis of cholesterol and glucose.

The Fuster-BEWAT score evaluates five health indicators: blood pressure, physical activity, body-mass index, fruit and vegetable intake, and smoking status, and does not require a blood test. These results demonstrate the usefulness of the Fuster-BEWAT score as an index of subclinical atherosclerosis.

The study, carried out at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, Spain, demonstrates that the Fuster-BEWAT score effectively predicts the presence and extent of subclinical (asymptomatic) atherosclerosis in healthy middle-aged individuals with no known history of cardiovascular disease. Moreover, Fuster-BEWAT predictions are as accurate as those obtained with the widely used ICHS.

Previous studies, like the PURE study, coordinated by Salim Yusuf, MD and recently published in The Lancet, had already indicated that blood analysis can sometimes be omitted from cardiovascular risk calculations, a particular advantage in regions with limited health care resources.

Researchers from the Icahn School of Medicine at Mount Sinai, CNIC, and other institutions studied 3,983 middle-aged participants without prior cardiovascular disease who were employees of the Banco de Santander in Madrid. This is an ongoing observational prospective cohort study in which participants are being followed for 10 years. The results demonstrate the usefulness of the Fuster-BEWAT score for evaluating cardiovascular risk in situations where it is not possible to obtain blood samples.

“The Fuster-BEWAT score may be particularly relevant in low-resource areas, such as developing countries, where the burden of cardiovascular disease is growing faster than in the rest of the world,” said the study’s corresponding author, Valentin Fuster, M.D., Ph.D., director of Mount Sinai Heart and physician-in-chief of The Mount Sinai Hospital. “The Fuster-BEWAT score is an easy, painless, inexpensive tool that could be implemented in resource-constrained health care settings to identify individuals with a high likelihood of subclinical atherosclerosis at whom preventative management strategies can be directed.”

The study is part of an international initiative that is being conducted through partnerships with the National Center for Cardiovascular Research in Spain, the Icahn School of Medicine at Mount Sinai and the Framingham Heart Study.

Follow up studies in the research cohort will investigate if participants showing ideal ICHS and Fuster-BEWAT metrics have less progression of subclinical atherosclerosis and lower incidence of clinical events over time.

For more information: www.mountsinai.org

Related Content

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

News | Cardiac Diagnostics | July 29, 2021
July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation Ambula
The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

News | Cardiac Diagnostics | July 01, 2021
July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc.
Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Detecting heart disease with OCT imaging of the eye.Getty Images

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Getty Images
 

News | Cardiac Diagnostics | March 08, 2021
March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potent
Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia.

Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG strip on a smartphone. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia. 

News | Cardiac Diagnostics | March 03, 2021
March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management s
A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images Health disparities in cardiovascular disease.

A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images

News | Cardiac Diagnostics | February 02, 2021
February 2, 2021 — A new study has found in the U.S.
A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en